In short
Dordaviprone, also known as ONC201, is an innovative drug being studied in various clinical trials for its potential in treating different types of cancer. This article explores the ongoing research on dordaviprone, focusing on its use in gliomas, endometrial cancer, and colorectal cancer prevention. We'll examine the drug's mechanism of action, its administration in different trials, and the preliminary findings from these studies.
At a glance
- Drug Name
- Dordaviprone (ONC201)
- Mechanism of Action
- ClpP agonist and DRD2 antagonist
- Main Cancer Types Studied
- Gliomas (especially H3 K27M-mutant), DIPG, Endometrial Cancer, Colorectal Cancer Prevention
- Administration
- Oral (capsules), various dosing schedules (weekly, twice weekly)
- Key Outcomes Measured
- Progression-free survival, Overall survival, Tumor response, Safety and tolerability
- Notable Trial Phases
- Phase 1, Phase 2, Phase 3
- Special Populations
- Pediatric patients, Adults with specific mutations or cancer types
- Biomarkers of Interest
- H3 K27M mutation, TRAIL expression
What is Dordaviprone?
Dordaviprone, also known as ONC201 or TIC10, is an experimental drug currently being studied for its potential in treating various types of cancer and preventing colorectal cancer. This medication is part of a new class of drugs that work in unique ways to target cancer cells.
How Does Dordaviprone Work?
Dordaviprone works through multiple mechanisms to fight cancer cells:
- ClpP agonist: It activates a protein called ClpP, which helps to break down other proteins in cancer cells.
- DRD2 antagonist: It blocks a receptor called DRD2, which is involved in cancer cell growth.
- Akt/ERK inhibitor: It blocks enzymes called Akt and ERK, which are important for cancer cell survival and growth.
- TRAIL inducer: It increases the production of a protein called TRAIL, which can cause cancer cells to die.
These combined actions may help to stop the growth of tumor cells and potentially kill them.
Conditions Treated with Dordaviprone
Dordaviprone is being studied for several types of cancer and precancerous conditions:
- Gliomas: These are tumors that occur in the brain and spinal cord. Dordaviprone is particularly being studied for a specific type called H3 K27M-mutant glioma.
- Colorectal Cancer Prevention: It's being tested to see if it can prevent colorectal cancer in people at high risk, such as those with familial adenomatous polyposis (FAP) or multiple polyps.
Clinical Trials and Research
Several clinical trials are currently underway to study dordaviprone:
- Expanded Access for Glioma Patients: This program provides dordaviprone to patients with H3 K27M-mutant and/or midline gliomas who can't access the drug through other clinical trials.
- The ACTION Study: This is a large Phase 3 trial testing dordaviprone in patients with newly diagnosed H3 K27M-mutant diffuse glioma. It's looking at whether the drug can extend overall survival and progression-free survival when given after radiotherapy.
- Colorectal Cancer Prevention Trial: This Phase 1 trial is testing dordaviprone's safety and effectiveness in preventing colorectal cancer in high-risk individuals.
Dosage and Administration
The dosage of dordaviprone can vary depending on the specific trial and patient characteristics:
- In the ACTION study, patients weighing 52.5 kg or more receive 625 mg (5 x 125-mg capsules) on dosing days. Patients weighing less than 52.5 kg receive a dose scaled to their body weight.
- The drug is typically taken orally (by mouth) either once weekly or once every 3 weeks.
It's important to note that as dordaviprone is still in clinical trials, the optimal dosage may not yet be established and could change based on research findings.
Potential Side Effects
As dordaviprone is still in clinical trials, all of its potential side effects are not yet fully known. The ongoing studies are closely monitoring for any adverse events. Some areas being specifically watched include:
- Changes in laboratory test results
- Effects on corticosteroid use
- Changes in performance status (a measure of a patient's ability to perform daily activities)
- Changes in prolactin levels (a hormone) in the blood
Patients in clinical trials are closely monitored for any side effects or adverse events. If you're considering participating in a clinical trial for dordaviprone, it's important to discuss potential risks and benefits with your healthcare provider.